Editas Medicine Announces Third Quarter 2026 Results and Business Updates
Editas Medicine, Inc. (EDIT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Editas Medicine Annou nces Third Quarter 2026 Results and Bu siness Updates Company received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia New preclinical data presented at AHA Scientific Sessions demonstrating ≥90 perc
How this was made
The 30-second read
Why it matters
The Q3 filing provides the first public update on the Strive study initiation and preclinical durability data, which are material to the company's valuation.
Market read
First‑time earnings and pipeline update for a mid‑cap biotech; could move EDIT relative to peers.
What to watch
Cash runway only extends to H2 2028; future financing needs and competition in lipid‑lowering therapies could pressure the stock.
Editas reports Q3 2026 net loss of $(23,393) thousand, or $(0.15) per share, versus $(25,117) thousand, or $(0.28), a year earlier, with EDIT-401 Strive study HREC approval in Australia and cash runway into the second half of 2028
Quarterly net loss narrowed versus the prior-year quarter and collaboration revenue rose to $10,365 thousand from $7,543 thousand, but the company attributes the revenue increase to clinical milestones achieved by a partner, operating loss was broadly flat at $(24,282) thousand against $(24,548) thousand, and the filing gives no guidance.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Collaboration and other research and development revenues, Q3 2026 (three months ended Sept 30)GAAP | $10.37M | – | – |
| Research and development expenses, Q3 2026 (three months ended Sept 30)GAAP | $21.17M | – | $1.4 million increase |
| General and administrative expenses, Q3 2026 (three months ended Sept 30)GAAP | $13.48M | – | $1.2 million increase |
| Restructuring and impairment charges, Q3 2026 (three months ended Sept 30)GAAP | not reported (shown as a dash in the statement) | – | – |
| Total operating expenses, Q3 2026 (three months ended Sept 30)GAAP | $34.65M | – | – |
| Operating loss, Q3 2026 (three months ended Sept 30)GAAP | −$24.28M | – | – |
| Interest expense related to sale of future revenues, Q3 2026 (three months ended Sept 30)GAAP | −$1.08M | – | – |
| Interest income, net, Q3 2026 (three months ended Sept 30)GAAP | $1.97M | – | – |
| Other expense, net, Q3 2026 (three months ended Sept 30)GAAP | −$1K | – | – |
| Total other income (expense), net, Q3 2026 (three months ended Sept 30)GAAP | $889K | – | – |
| Net loss attributable to common stockholders, Q3 2026 (three months ended Sept 30)GAAP | −$23.39M | – | – |
| Net loss per share, basic and diluted, Q3 2026 (three months ended Sept 30)GAAP | $(0.15) | – | – |
| Collaboration and other research and development revenues, nine months ended Sept 30, 2026GAAP | $25.09M | – | – |
| Research and development expenses, nine months ended Sept 30, 2026GAAP | $58.95M | – | – |
| General and administrative expenses, nine months ended Sept 30, 2026GAAP | $35.31M | – | – |
| Restructuring and impairment charges, nine months ended Sept 30, 2026GAAP | −$1.34M | – | – |
| Total operating expenses, nine months ended Sept 30, 2026GAAP | $92.92M | – | – |
| Operating loss, nine months ended Sept 30, 2026GAAP | −$67.84M | – | – |
| Interest expense related to sale of future revenues, nine months ended Sept 30, 2026GAAP | −$3.21M | – | – |
| Interest income, net, nine months ended Sept 30, 2026GAAP | $4.55M | – | – |
| Other expense, net, nine months ended Sept 30, 2026GAAP | −$97K | – | – |
| Total other income (expense), net, nine months ended Sept 30, 2026GAAP | $1.23M | – | – |
| Net loss, nine months ended Sept 30, 2026GAAP | −$66.61M | – | – |
| Net loss per share, basic and diluted, nine months ended Sept 30, 2026GAAP | $(0.54) | – | – |
| Cash, cash equivalents and marketable securities, as of Sept 30, 2026GAAP | $190.2M | – | – |
| Cash and cash equivalents, as of Sept 30, 2026GAAP | $93.17M | – | – |
| Total assets, as of Sept 30, 2026GAAP | $219.4M | – | – |
| Total stockholders' equity, as of Sept 30, 2026GAAP | $84.52M | – | – |
Capital returns
- The filing prints no share repurchases and no dividends for the period.
What drove it
- Company explanation for the collaboration revenue increase: primarily attributable to revenue recognized in connection with clinical development milestones achieved by a strategic partner.
- Company explanation for the R&D increase: primarily related to higher sublicense and license fees as well as increased costs associated with the continued development of EDIT-401, partially offset by lower employee-related costs and external research and development costs.
- Company explanation for the G&A increase: primarily attributable to higher intellectual property and patent-related fees due to increased legal activity related to intellectual property defense.
- Interest expense related to sale of future revenues fell to $(1,082) thousand from $(2,399) thousand in the quarter, and the filing does not explain this change.
- A second IND/CTA was accepted under the Bristol Myers Squibb collaboration, which the release says triggered a milestone payment to Editas. The payment amount is not printed.
Concerns
- Net loss per share fell to $(0.15) from $(0.28), but weighted-average shares rose sharply during the period; the filing does not state the effect of share issuance on the per-share comparison beyond the printed share counts.
- Nine-month collaboration revenue of $25,086 thousand includes the restructuring credit of $(1,339) thousand in nine-month operating expenses, so nine-month operating loss comparisons with the prior year reflect a $66,935 thousand restructuring charge in 2025.
- Cash and cash equivalents fell to $93,169 thousand from $146,645 thousand at December 31, 2025, while total cash, cash equivalents and marketable securities were $190.2 million.
- Stockholders' equity was $84,520 thousand at September 30, 2026, compared with $27,288 thousand at December 31, 2025.
- General and administrative expenses rose to $13,477 thousand, which the company attributes to increased intellectual property and patent-related legal activity.
- The release is positioned around EDIT-401 clinical milestones, which are forward-looking and subject to the risks listed in the release.
What to watch
- Patient dosing in the Strive study of EDIT-401 in Australia, which the company says remains on track for this year.
- Initial safety and tolerability data from the Strive study, which the company expects in the first quarter of 2027.
- Completion of enrollment in Part 1 of the Strive study and topline safety and efficacy results from Part 1, which the company expects in the second half of 2027.
- Further EDIT-401 data in 2027, as referenced by the CEO.
- Milestone revenue from the Bristol Myers Squibb collaboration, given that collaboration revenue in the quarter was attributed to partner milestones.
- Cash runway into the second half of 2028, which the company says extends through and beyond key clinical readouts from the Strive study.
- Fireside chat at the 9th Annual Evercore Healthcare Conference on November 30, 2026, at 3:25 p.m. ET.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $190.2 million as of September 30, 2026, compared with $146.6 million as of December 31, 2025, as stated in the release text.
- Balance sheet detail as of September 30, 2026 versus December 31, 2025: cash and cash equivalents $93,169 thousand versus $146,645 thousand; marketable securities $97,029 thousand versus not reported (shown as a dash); total assets $219,412 thousand versus $186,534 thousand; total stockholders' equity $84,520 thousand versus $27,288 thousand.
- The company expects its existing cash, cash equivalents and marketable securities will fund operating expenses and capital expenditure requirements into the second half of 2028.
- No operating cash flow, free cash flow or cash flow statement is printed in the filing.
Analysis
Editas reported a third quarter 2026 net loss attributable to common stockholders of $(23,393) thousand, or $(0.15) per share, compared with $(25,117) thousand, or $(0.28) per share, in the same quarter of 2025. Collaboration and other research and development revenues rose to $10,365 thousand from $7,543 thousand. The company attributes the increase primarily to revenue recognized on clinical development milestones achieved by a strategic partner, so the quarter's revenue is milestone-driven rather than a recurring product or service stream. Total operating expenses were $34,647 thousand against $32,091 thousand, with R&D at $21,170 thousand (up $1.4 million as the release states) and G&A at $13,477 thousand (up $1.2 million). Operating loss was $(24,282) thousand against $(24,548) thousand, so the narrower net loss owed more to other income than to operating performance. Total other income, net was $889 thousand against $(569) thousand, with interest income, net of $1,972 thousand and interest expense related to sale of future revenues of $(1,082) thousand.
On a nine-month basis, the comparison is distorted by the 2025 restructuring line. Nine-month restructuring and impairment charges were $66,935 thousand in 2025, against a $(1,339) thousand credit in 2026, so nine-month total operating expenses fell to $92,925 thousand from $168,034 thousand and the nine-month net loss narrowed to $(66,605) thousand from $(154,440) thousand. Nine-month R&D fell to $58,950 thousand from $62,549 thousand and G&A fell to $35,314 thousand from $38,550 thousand. Nine-month collaboration revenue rose to $25,086 thousand from $15,779 thousand.
The balance sheet shows cash, cash equivalents and marketable securities of $190.2 million at September 30, 2026, against $146.6 million at December 31, 2025. Within that total, cash and cash equivalents were $93,169 thousand and marketable securities were $97,029 thousand. Total assets rose to $219,412 thousand from $186,534 thousand, and stockholders' equity rose to $84,520 thousand from $27,288 thousand. Deferred revenue, current, of $32,315 thousand appears on the balance sheet against a dash at December 31, 2025, and the release does not explain it. The company states that existing resources will fund operating expenses and capital expenditure requirements into the second half of 2028. No operating or free cash flow figures are printed, so the quarter's cash burn cannot be read directly from the filing.
The release is weighted toward EDIT-401 development. The company reports that Australia's HREC approved and the CTN process was completed for the Phase 1/2 Strive study in patients with HeFH, that patient dosing is expected this year, that initial safety and tolerability data are expected in the first quarter of 2027, and that topline Part 1 results are expected in the second half of 2027. Preclinical data presented at AHA reported LDL-C reduction of 90 percent or more maintained over 10 months in non-human primates. The release does not give quantitative clinical data, and the preclinical results cannot be read as clinical outcomes. A second IND/CTA was accepted under the Bristol Myers Squibb collaboration, which the company says triggered a milestone payment, but the payment amount is not disclosed.
The filing contains no financial guidance, no capital return activity and no segment reporting. Items the reader should weigh are the reliance on partner milestones for revenue, the step-up in G&A tied to intellectual property defense, the sharp rise in weighted-average shares, and the decline in cash and cash equivalents over the nine months, which the filing does not reconcile to a cash flow statement.
Management, verbatim
Backed by this momentum and our strong cash position, we look forward to executing on the Strive study and generating additional data in 2027.
Gilmore O'Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine
Not in the filing
stated, not guessed- No financial guidance for 2026 or later was provided, and no previous outlook was supplied for comparison.
- No consensus estimates, analyst expectations or share price reaction are in the filing.
- The prior-year comparison for balance sheet items is December 31, 2025, which is not a same-period prior-year figure, so prior_year is set to null for balance sheet rows.
- Marketable securities at December 31, 2025 is shown as a dash in the filing; no figure is reported.
- No operating cash flow, investing cash flow, financing cash flow or free cash flow is printed.
- No segment or geographic revenue breakdown is printed beyond collaboration and other research and development revenues.
- The amount of the milestone payment triggered by the second IND/CTA acceptance is not disclosed.
- No percentage changes are printed for any line item; yoy_change and qoq_change are null where no change figure is stated.
- No prior-quarter (Q2 2026) figures are printed, so prior_quarter is null for all rows.
- No non-GAAP measures are printed in the filing.
- The reason for the deferred revenue, current balance of $32,315 thousand is not explained in the filing.
- No share repurchases or dividends are reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Editas Medicine (NASDAQ: EDIT) is a CRISPR‑based gene‑editing company focusing on rare diseases and cardiovascular therapies.
Ticker impact
Editas Medicine filed its 8‑K reporting Q3 2026 results, new cash balance, loss per share, and progress on the EDIT‑401 gene‑editing program.
potential modest upside as the narrowed loss and cash runway could attract buying, though biotech risk remains
First‑time disclosure of results and regulatory approval provides fresh material; market typically reacts to improved loss metrics and pipeline milestones.
Market effects
Positive signal for the gene‑editing/biotech sector as a leading player reports pipeline progress.
Limited to US biotech equities; no broader regional effect.
Modest; may influence investor sentiment toward CRISPR‑based therapeutics globally.
Counterpoint
The loss, though narrowed, remains sizable; investors may stay cautious until clinical data are confirmed in humans.
Key entities
- companyEditas Medicine
NASDAQ‑listed gene‑editing biotech.
- partnerBristol Myers Squibb
Collaborator on the CD70 CAR‑T program.
